Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.

Copeland BT, Du J, Pal SK, Jones JO.

Mol Oncol. 2019 Sep 14. doi: 10.1002/1878-0261.12572. [Epub ahead of print]

2.

Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer.

Salgia MM, Elix CC, Pal SK, Jones JO.

Am J Clin Exp Urol. 2019 Jun 15;7(3):98-109. eCollection 2019.

3.

Impaired Driving Associated with the Synthetic Cannabinoid 5f-Adb.

McCain KR, Jones JO, Chilbert KT, Patton AL, James LP, Moran JH.

J Forensic Sci Criminol. 2018 Aug;6(1). doi: 10.15744/2348-9804.6.105.

4.

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium.

Pal SK, Tew BY, Lim M, Stankavich B, He M, Pufall M, Hu W, Chen Y, Jones JO.

ACS Omega. 2019 Feb 28;4(2):2472-2481. doi: 10.1021/acsomega.8b03205. Epub 2019 Feb 1.

5.

A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy.

Flint TR, Jones JO, Ferrer M, Colucci F, Janowitz T.

Semin Oncol. 2018 Jun;45(3):170-175. doi: 10.1053/j.seminoncol.2018.03.005. Epub 2018 Mar 26. Review.

PMID:
30262396
6.

Multi-laboratory validation of a Δ9-tetrahydrocannabinol LC-MS/MS test kit designed for quantifying THC and marijuana metabolites in blood.

Patton AL, Jones JO, Nord A, Eversole DW, Feazell EE, Mauldin K, Li L, Williams LD, Bai S, Channell K, Endres G, Gamette M, Moran JH.

Forensic Sci Criminol. 2018;3(1). doi: 10.15761/FSC.1000125. Epub 2018 Mar 28.

7.

"I don't want to take any risks even if it's gonna mean this service-user is gonna be happier": A thematic analysis of community support staff perspectives on delivering Transforming Care.

Clifford A, Standen PJ, Jones J.

J Appl Res Intellect Disabil. 2018 Nov;31(6):1209-1218. doi: 10.1111/jar.12495. Epub 2018 Jun 27.

PMID:
29947457
8.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.

PMID:
29685646
9.

The androgen receptor malignancy shift in prostate cancer.

Copeland BT, Pal SK, Bolton EC, Jones JO.

Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23. Review.

PMID:
29473182
10.

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.

11.

BIRTH OF A MIDWIFE.

Jones J.

Aust Nurs Midwifery J. 2017 May;24(10):28.

PMID:
29274269
12.

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.

Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19.

13.

The role of peroxisome proliferator-activated receptor gamma in prostate cancer.

Elix C, Pal SK, Jones JO.

Asian J Androl. 2018 May-Jun;20(3):238-243. doi: 10.4103/aja.aja_15_17. Review.

14.

Identification of neuron selective androgen receptor inhibitors.

Otto-Duessel M, Tew BY, Vonderfecht S, Moore R, Jones JO.

World J Biol Chem. 2017 May 26;8(2):138-150. doi: 10.4331/wjbc.v8.i2.138.

15.

A preliminary investigation to explore the cognitive resources of physicians experiencing difficulty in training.

Patterson F, Cousans F, Coyne I, Jones J, Macleod S, Zibarras L.

BMC Med Educ. 2017 May 15;17(1):87. doi: 10.1186/s12909-017-0918-z.

16.

A role for virtue in unifying the 'knowledge' and 'caring' discourses in nursing theory.

Bliss S, Baltzly D, Bull R, Dalton L, Jones J.

Nurs Inq. 2017 Oct;24(4). doi: 10.1111/nin.12191. Epub 2017 Feb 28.

PMID:
28247531
17.

Vitamin K epoxide reductase regulation of androgen receptor activity.

Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO.

Oncotarget. 2017 Feb 21;8(8):13818-13831. doi: 10.18632/oncotarget.14639.

18.

Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.

Zhou Y, Copeland B, Otto-Duessel M, He M, Markel S, Synold TW, Jones JO.

Prostate. 2017 Apr;77(5):530-541. doi: 10.1002/pros.23290. Epub 2016 Dec 14.

PMID:
27976414
19.

Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).

Wang C, Zhao Q, Vargas M, Jones JO, White KL, Shackleford DM, Chen G, Saunders J, Ng AC, Chiu FC, Dong Y, Charman SA, Keiser J, Vennerstrom JL.

J Med Chem. 2016 Dec 8;59(23):10705-10718. Epub 2016 Nov 28.

20.

Vitamin K epoxide reductase expression and prostate cancer risk.

Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO.

Urol Oncol. 2017 Mar;35(3):112.e13-112.e18. doi: 10.1016/j.urolonc.2016.10.020. Epub 2016 Nov 23.

PMID:
27889279
21.

Biomarkers in Genitourinary Cancers: Blazing the Path Forward.

Pal SK, Karam JA, Chennamsetty A, Jones JO.

Eur Urol. 2017 Feb;71(2):247-248. doi: 10.1016/j.eururo.2016.09.011. Epub 2016 Sep 14. No abstract available.

PMID:
27639532
22.

High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.

Vuong W, Tew BY, Little GH, Frenkel B, Jones JO.

J Pharmacol Exp Ther. 2016 Nov;359(2):256-261. Epub 2016 Aug 23.

PMID:
27554677
23.

Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ.

PLoS One. 2016 Mar 21;11(3):e0152243. doi: 10.1371/journal.pone.0152243. eCollection 2016. No abstract available.

24.

Demystifying professional support for trainees: what does it mean?

Goodyear H, Jones J.

Br J Hosp Med (Lond). 2016 Feb;77(2):107-10. doi: 10.12968/hmed.2016.77.2.107.

PMID:
26875805
25.

Current Contraceptive Use and Variation by Selected Characteristics Among Women Aged 15-44: United States, 2011-2013.

Daniels K, Daugherty J, Jones J, Mosher W.

Natl Health Stat Report. 2015 Nov 10;(86):1-14.

26.

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.

Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO.

Mol Cancer Ther. 2015 Dec;14(12):2896-900. doi: 10.1158/1535-7163.MCT-15-0367. Epub 2015 Oct 8.

27.

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ.

PLoS One. 2015 Jul 21;10(7):e0131232. doi: 10.1371/journal.pone.0131232. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0152243. Liu, Xiuqing [corrected to Li, Xiuqing].

28.

Nonuse of contraception among women at risk of unintended pregnancy in the United States.

Mosher W, Jones J, Abma J.

Contraception. 2015 Aug;92(2):170-6. doi: 10.1016/j.contraception.2015.05.004. Epub 2015 May 19.

29.

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Pal SK, Agarwal N, Jones JO.

Cancer. 2015 Sep 15;121(18):3190-2. doi: 10.1002/cncr.29454. Epub 2015 May 14. No abstract available.

30.
31.

Current contraceptive status among women aged 15-44: United States, 2011-2013.

Daniels K, Daugherty J, Jones J.

NCHS Data Brief. 2014 Dec;(173):1-8.

32.

Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer.

Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO.

Clin Genitourin Cancer. 2015 Apr;13(2):130-6. doi: 10.1016/j.clgc.2014.08.014. Epub 2014 Sep 22.

33.

Androgens and androgen receptor signaling in prostate tumorigenesis.

Zhou Y, Bolton EC, Jones JO.

J Mol Endocrinol. 2015 Feb;54(1):R15-29. doi: 10.1530/JME-14-0203. Epub 2014 Oct 28. Review.

PMID:
25351819
34.

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.

Pal SK, Hossain DM, Zhang Q, Frankel PH, Jones JO, Carmichael C, Ruel C, Lau C, Kortylewski M.

J Urol. 2015 Apr;193(4):1114-21. doi: 10.1016/j.juro.2014.09.110. Epub 2014 Oct 5.

PMID:
25286010
35.

RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO.

Mol Cancer Res. 2015 Jan;13(1):130-7. doi: 10.1158/1541-7786.MCR-14-0352. Epub 2014 Sep 2.

36.

Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.

Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):292-9. doi: 10.1038/pcan.2014.27. Epub 2014 Jul 22.

PMID:
25047002
37.

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.

Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B.

Cancer Res. 2014 May 15;74(10):2857-68. doi: 10.1158/0008-5472.CAN-13-2003. Epub 2014 Mar 19.

38.

Fathers' involvement with their children: United States, 2006-2010.

Jones J, Mosher WD.

Natl Health Stat Report. 2013 Dec 20;(71):1-21.

39.

Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.

Lim M, Otto-Duessel M, He M, Su L, Nguyen D, Chin E, Alliston T, Jones JO.

ACS Chem Biol. 2014 Mar 21;9(3):692-702. doi: 10.1021/cb400759d. Epub 2014 Jan 3.

40.

Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease.

Pal SK, Ruel N, Vogelzang N, Chang M, Wilson TG, Jones JO, Yuh B.

Clin Genitourin Cancer. 2014 Jun;12(3):149-54. doi: 10.1016/j.clgc.2013.11.009. Epub 2013 Nov 12.

41.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

42.

TOX3 mutations in breast cancer.

Jones JO, Chin SF, Wong-Taylor LA, Leaford D, Ponder BA, Caldas C, Maia AT.

PLoS One. 2013 Sep 19;8(9):e74102. doi: 10.1371/journal.pone.0074102. eCollection 2013.

43.

Use of emergency contraception among women aged 15-44: United States, 2006-2010.

Daniels K, Jones J, Abma J.

NCHS Data Brief. 2013 Feb;(112):1-8.

44.

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.

Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT.

J Exp Med. 2013 Jun 3;210(6):1137-51. doi: 10.1084/jem.20122344. Epub 2013 May 27.

45.

Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Zhou Y, Otto-Duessel M, He M, Markel S, Synold T, Jones JO.

J Mol Endocrinol. 2013 Jun 29;51(1):143-53. doi: 10.1530/JME-13-0060. Print 2013.

46.

Conceptual issues in neurodevelopmental disorders: lives out of synch.

Clegg J, Gillott A, Jones J.

Curr Opin Psychiatry. 2013 May;26(3):289-94. doi: 10.1097/YCO.0b013e32835f6771. Review.

PMID:
23519204
47.

Enhanced evaluation of selective androgen receptor modulators in vivo.

Otto-Duessel M, He M, Adamson TW, Jones JO.

Andrology. 2013 Jan;1(1):29-36. doi: 10.1111/j.2047-2927.2012.00006.x. Epub 2012 Aug 28.

48.

Intended and unintended births in the United States: 1982-2010.

Mosher WD, Jones J, Abma JC.

Natl Health Stat Report. 2012 Jul 24;(55):1-28.

49.

Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995.

Jones J, Mosher W, Daniels K.

Natl Health Stat Report. 2012 Oct 18;(60):1-25.

50.

Effects of parabens on adipocyte differentiation.

Hu P, Chen X, Whitener RJ, Boder ET, Jones JO, Porollo A, Chen J, Zhao L.

Toxicol Sci. 2013 Jan;131(1):56-70. doi: 10.1093/toxsci/kfs262. Epub 2012 Sep 5.

Supplemental Content

Loading ...
Support Center